HC Wainwright Has Negative Outlook for EYPT FY2024 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a research report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.15) per share for the year, down from their prior forecast of ($2.09). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

Several other equities analysts have also weighed in on the stock. Chardan Capital lifted their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 8th. Jefferies Financial Group initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 target price for the company. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Robert W. Baird decreased their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Scotiabank assumed coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.00.

EyePoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $10.76 on Thursday. EyePoint Pharmaceuticals has a 1-year low of $5.86 and a 1-year high of $30.99. The business’s 50-day simple moving average is $9.66 and its 200-day simple moving average is $9.91. The firm has a market capitalization of $575.88 million, a P/E ratio of -5.38 and a beta of 1.50.

Institutional Trading of EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in EYPT. Charles Schwab Investment Management Inc. lifted its position in EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of EyePoint Pharmaceuticals during the third quarter valued at approximately $136,000. GSA Capital Partners LLP boosted its position in shares of EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after buying an additional 18,616 shares during the period. Greenwich Wealth Management LLC grew its holdings in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after buying an additional 900 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after acquiring an additional 4,172 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.